Beyond Eosinophils: Proteomics to Identify Potential Biomarkers of Organ Damage and Response to MEPOLIZUMAB in EGPA
Phase: PHASE4
Conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma, Eosinophilic Asthma
Sponsor: Azienda Ospedaliero Universitaria di Cagliari

 
 
 
Beyond eosinophils: proteomics to identify potential biomarkers of organ damage 
and response to MEPOLIZUMAB in EGPA 
 
Protocol Number: 14918 
 
Compound Number or Name: BEOMICS study 
 
Brief Title: Beyond EOsinophils: proteoMICS to identify potential biomarker of organ 
damage and response to MEPOLIZUMAB in EGPA 
 
NCT number: n.a. 
 
Date of the document: 12 february 2023